Proving this concept with the highly immunogenic FVIII protein could allow for expansion of this strategy for other diseases complicated by an immune response to biotherapeutics: for instance, hemophilia B and/or enzyme replacement therapy in other genetic diseases. The gene discussed is F8; the disease is hereditary disease.